Tufton Capital Management Abb Vie Inc. Transaction History

Tufton Capital Management

$532 Million
Q3 2024

A detailed history of Tufton Capital Management transactions in Abb Vie Inc. stock. As of the latest transaction made, Tufton Capital Management holds 57,877 shares of ABBV stock, worth $9.82 Million. This represents 2.15% of its overall portfolio holdings.

Number of Shares

57,877

Previous 58,909 1.75%

Holding current value

$9.82 Million

Previous $10.1 Million 13.11%

% of portfolio

2.15%

Previous 1.97%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$163.84 - $199.33 $169,082 - $205,708	-1,032 Reduced 1.75%	57,877 $11.4 Million
Q2 2024 Jul 31, 2024	SELL	$154.79 - $180.76 $24,766 - $28,921	-160 Reduced 0.27%	58,909 $10.1 Million
Q1 2024 May 07, 2024	BUY	$159.82 - $182.1 $9.44 Million - $10.8 Million	59,069 New	59,069 $10.8 Million
Q4 2023 Jan 31, 2024	SELL	$137.6 - $154.97 $94,944 - $106,929	-690 Reduced 1.15%	59,460 $9.21 Million
Q3 2023 Oct 30, 2023	SELL	$133.59 - $154.65 $29,656 - $34,332	-222 Reduced 0.37%	60,150 $8.97 Million
Q2 2023 Jul 28, 2023	BUY	$132.51 - $164.9 $8 Million - $9.96 Million	60,372 New	60,372 $8.13 Million
Q1 2023 Apr 19, 2023	SELL	$144.61 - $166.54 $1.53 Million - $1.76 Million	-10,596 Reduced 14.52%	62,379 $9.94 Million
Q4 2022 Jan 26, 2023	SELL	$138.31 - $165.87 $50,483 - $60,542	-365 Reduced 0.5%	72,975 $0
Q3 2022 Oct 21, 2022	SELL	$134.21 - $153.93 $5.02 Million - $5.76 Million	-37,389 Reduced 33.77%	73,340 $9.84 Million
Q2 2022 Jul 20, 2022	SELL	$137.62 - $174.96 $987,973 - $1.26 Million	-7,179 Reduced 6.09%	110,729 $17 Million
Q1 2022 Apr 25, 2022	SELL	$131.98 - $163.75 $425,899 - $528,421	-3,227 Reduced 2.66%	117,908 $19.1 Million
Q4 2021 Jan 28, 2022	BUY	$107.43 - $135.93 $28,576 - $36,157	266 Added 0.22%	121,135 $16.4 Million
Q3 2021 Oct 21, 2021	SELL	$106.4 - $120.78 $229,079 - $260,039	-2,153 Reduced 1.75%	120,869 $13 Million
Q2 2021 Jul 29, 2021	SELL	$105.21 - $117.21 $252,819 - $281,655	-2,403 Reduced 1.92%	123,022 $13.9 Million
Q1 2021 Apr 22, 2021	BUY	$102.3 - $112.62 $498,201 - $548,459	4,870 Added 4.04%	125,425 $13.6 Million
Q4 2020 Feb 01, 2021	BUY	$80.49 - $108.67 $361,239 - $487,710	4,488 Added 3.87%	120,555 $12.9 Million
Q3 2020 Oct 23, 2020	BUY	$85.91 - $100.83 $5,584 - $6,553	65 Added 0.06%	116,067 $10.2 Million
Q2 2020 Jul 27, 2020	BUY	$73.37 - $98.18 $18,709 - $25,035	255 Added 0.22%	116,002 $11.4 Million
Q1 2020 Apr 23, 2020	BUY	$64.5 - $97.79 $11,029 - $16,722	171 Added 0.15%	115,747 $8.82 Million
Q4 2019 Jan 24, 2020	BUY	$72.13 - $90.25 $64,772 - $81,044	898 Added 0.78%	115,576 $10.2 Million
Q3 2019 Oct 25, 2019	SELL	$62.98 - $75.72 $570,661 - $686,098	-9,061 Reduced 7.32%	114,678 $8.68 Million
Q2 2019 Jul 26, 2019	SELL	$65.7 - $83.98 $7.97 Million - $10.2 Million	-121,279 Closed	0 $0
Q1 2019 Apr 29, 2019	BUY	$77.14 - $90.79 $501,410 - $590,135	6,500 Added 5.66%	121,279 $9.77 Million
Q4 2018 Jan 28, 2019	BUY	$77.85 - $96.01 $126,428 - $155,920	1,624 Added 1.44%	114,779 $10.6 Million
Q3 2018 Oct 26, 2018	SELL	$88.91 - $98.84 $566,534 - $629,808	-6,372 Reduced 5.33%	113,155 $10.7 Million
Q2 2018 Aug 06, 2018	SELL	$89.78 - $106.23 $50,187 - $59,382	-559 Reduced 0.47%	119,527 $11.1 Million
Q1 2018 Apr 23, 2018	SELL	$92.01 - $123.21 $406,500 - $544,341	-4,418 Reduced 3.55%	120,086 $11.4 Million
Q4 2017 Jan 26, 2018	SELL	$89.56 - $98.21 $1.16 Million - $1.27 Million	-12,908 Reduced 9.39%	124,504 $12 Million
Q3 2017 Oct 20, 2017	BUY	$69.85 - $89.22 $9.6 Million - $12.3 Million	137,412	137,412 $12.2 Million

Others Institutions Holding ABBV

# of Institutions

3,837

Shares Held

1.25B

Call Options Held

15.7M

Put Options Held

11.3M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $300B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tufton Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Tufton Capital Management with notifications on news.

Account

Tufton Capital Management Abb Vie Inc. Transaction History